| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.24 | 4e-06 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.2 | 6e-06 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-05 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.16 | 4e-05 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.16 | 6e-05 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0002 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0003 |